FOXP2 and prostate neoplasm: In addition, we found that CNAs of FOXP2 were prominently enriched in ETS fusion-negative prostate tumors from the MSKCC/DFCI dataset (n = 685) (Armenia et al., 2018) (p=2.42 × 10–6, by Fisher’s exact test) (Figure 1—figure supplement 4F), suggesting that FOXP2 CNAs and ETS fusions were partially mutually exclusive.